相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: A discrete choice experiment
Kate A. Carey et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2022)
Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening
Stella Deng et al.
JOURNAL OF CHILD NEUROLOGY (2022)
Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA
Dylan Trundell et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2022)
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy
Eve Fouarge et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
Tamara Dangouloff et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study
Melanie Annoussamy et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Robert C. Sergott et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naive patients with spinal muscular atrophy (SMA) receiving risdiplam
C. Chiriboga et al.
NEUROMUSCULAR DISORDERS (2021)
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
Francois Boemer et al.
SCIENTIFIC REPORTS (2021)
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities
Laurent Servais et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2021)
Metabolic Dysfunction in Spinal Muscular Atrophy
Marc-Olivier Deguise et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
Basil T. Darras et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
Charlotte Lilien et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Risdiplam for the Use of Spinal Muscular Atrophy
Juyeon Kakazu et al.
ORTHOPEDIC REVIEWS (2021)
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2020)
New treatments in spinal muscular atrophy: an overview of currently available data
Sithara Ramdas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease
Crystal Jing Jing Yeo et al.
PEDIATRIC NEUROLOGY (2020)
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
Maria Carmela Pera et al.
PLOS ONE (2020)
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Tim Hagenacker et al.
LANCET NEUROLOGY (2020)
Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial
Francesco Muntoni et al.
NEUROMUSCULAR DISORDERS (2020)
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Ravindra N. Singh et al.
NEUROSCIENCE INSIGHTS (2020)
Structural basis of a small molecule targeting RNA for a specific splicing correction
Sebastien Campagne et al.
NATURE CHEMICAL BIOLOGY (2019)
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
Tamara Dangouloff et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
Stefan Sturm et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
Aurelie Chabanon et al.
PLOS ONE (2018)
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Agnes Poirier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy
Emmanuel Pinard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Enrico Bertini et al.
LANCET NEUROLOGY (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review
Ingrid E. C. Verhaart et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
Manaswini Sivaramakrishnan et al.
NATURE COMMUNICATIONS (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Developmental milestones in type I spinal muscular atrophy
Roberto De Sanctis et al.
NEUROMUSCULAR DISORDERS (2016)
Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study
Stephen J. Kolb et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy
Sarah Tisdale et al.
JOURNAL OF NEUROSCIENCE (2015)
Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?
Monir Shababi et al.
JOURNAL OF ANATOMY (2014)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Childhood spinal muscular atrophy: controversies and challenges
Eugenio Mercuri et al.
LANCET NEUROLOGY (2012)
DIGITAL NECROSES AND VASCULAR THROMBOSIS IN SEVERE SPINAL MUSCULAR ATROPHY
Sabine Rudnik-Schoeneborn et al.
MUSCLE & NERVE (2010)